PRESS RELEASE
Phase Holographic Imaging PHI AB (publ)
Lund, March 10, 2020

Gladstone Institutes, University of California and PHI form joint Center of Excellence

Gladstone Institutes, University of California in San Francisco (UCSF) and Phase Holographic Imaging (PHI) recently formed ***San Francisco's Center of Excellence for Holographic Imaging Cytometry***. The center is an expansion of the successful Center of Excellence program between UCSF and PHI, which has resulted in several scientific papers in prominent journals[1].

Supported by PHI, the center's activities focus on bringing the benefits of holographic cytometry and machine learning based on artificial intelligence. Apart from cutting-edge research, the Center will provide training and technical support to the surrounding research community in the San Francisco Bay Area.

Gladstone Institutes is an independent, non-profit life science research organization located in Mission Bay, the epicenter for biomedical and technological innovation in the San Francisco Bay Area. Gladstone attracts the brightest minds by promoting unconventional research and funding big ideas.

UCSF is part of the 10-campus University of California, the world's premier public research university system, and the only of its campuses exclusively dedicated to the health sciences and healthcare.

REFERENCES

[1] University of California San Francisco – Holographic Imaging Cytometry Center of Excellence

About PHI

Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Head-quartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Peter Egelberg, CEO
Tel: +46 703 19 42 74
E-mail: ir@phiab.se
Web: www.phiab.com